Compare Gilead Sciences, Inc. (GILD) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ABRDN Physical Gold Shares ETF — how do they compare? Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B), while ABRDN Physical Gold Shares ETF trades at $39.93 (market cap $7.03B). The key difference: Gilead Sciences, Inc. is far larger — about 25.9× ABRDN Physical Gold Shares ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| GILD | SGOL | |
|---|---|---|
Market Cap | $182.40B | $7.03B |
Volume | 4,469,821 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $155.80 | $51.41 |
52-Week Low | $116.74 | $37.54 |
Typical Hold Time | 111 Days | 57 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
SGOL trades at $39.94, up 2.36% with a bearish technical outlook showing 17 sell signals versus 2 buy signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent softer inflation data provided some support. Moving averages indicate strong bearish momentum while oscillators remain neutral, suggesting potential consolidation near current levels.
The outlook remains cautious with technical indicators favoring downside momentum, though oversold conditions could provide near-term support. Key risks include persistent inflation concerns and Fed policy uncertainty, while potential catalysts include geopolitical tensions and sustained gold demand from China. Investors should monitor Treasury yield movements and inflation data for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
